{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:22Z","timestamp":1761560002905},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/ico.0b013e3182772d4e","type":"journal-article","created":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T10:37:46Z","timestamp":1354012666000},"page":"835-838","source":"Crossref","is-referenced-by-count":32,"title":["Topical Application of Bevacizumab as an Adjunct to Recurrent Pterygium Surgery"],"prefix":"10.1097","volume":"32","author":[{"given":"Engin B.","family":"Ozgurhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Agca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Necip","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemal","family":"Yuksel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Demircan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Demirok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-22-20210204","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00167364","article-title":"The aetiology and histo-pathogenesis of pterygium. A review of the literature and a hypothesis.","volume":"31","author":"Peckar","year":"1972","journal-title":"Doc Ophthalmol"},{"key":"R2-22-20210204","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.eye.6701728","article-title":". Outcome of pterygium surgery: analysis over 14 years.","volume":"19","author":"Fernandes","year":"2005","journal-title":"Eye"},{"key":"R3-22-20210204","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/ICO.0b013e318033b3d4","article-title":"Comparison of conjunctival autograft with amniotic membrane transplantation for pterygium surgery: surgical and cosmetic outcome.","volume":"26","author":"Kucukerdonmez","year":"2007","journal-title":"Cornea"},{"key":"R4-22-20210204","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ICU.0b013e3281a7ecbb","article-title":"Current concepts and techniques in pterygium treatment.","volume":"18","author":"Ang","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"R5-22-20210204","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000151740","article-title":". Topical cyclosporine A in the prevention of pterygium recurrence.","volume":"222","author":"Yalcin Tok","year":"2008","journal-title":"Ophthalmologica"},{"key":"R6-22-20210204","first-page":"59","article-title":"VEGF and tumor angiogenesis.","volume":"18","author":"Terman","year":"2001","journal-title":"Einstein Quart J Biol Med"},{"key":"R7-22-20210204","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress.","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"R8-22-20210204","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R9-22-20210204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-540-73259-4_6","article-title":"Therapeutic anti-VEGF antibodies.","volume":"181","author":"Lien","year":"2008","journal-title":"Handbook Exp Pharmacol"},{"key":"R10-22-20210204","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","article-title":"Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R11-22-20210204","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08820530902801106","article-title":"Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.","volume":"24","author":"Mauro","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"R12-22-20210204","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICO.0b013e31818d382d","article-title":"Effect of subconjunctival bevacizumab on primary pterygium.","volume":"28","author":"Teng","year":"2009","journal-title":"Cornea"},{"key":"R13-22-20210204","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","article-title":". Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.","volume":"28","author":"Wu","year":"2009","journal-title":"Cornea"},{"key":"R14-22-20210204","first-page":"864","article-title":"Treatment of inamed pterygia or residual pterygial bed. Br J Ophthalmol..","volume":"93","author":"Mansour","year":"2009","journal-title":""},{"key":"R15-22-20210204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":". Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R16-22-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","article-title":". Efcacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.","volume":"35","author":"Fallah","year":"2010","journal-title":"Curr Eye Res"},{"key":"R17-22-20210204","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00347-009-1936-y","article-title":"Antiangiogenic therapy for pterygium recurrence in German.","volume":"106","author":"Leippi","year":"2009","journal-title":"Ophthalmologe"},{"key":"R18-22-20210204","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":". Preliminary results of subconjunctival bevacizumab in primary pterygium excision.","volume":"43","author":"Razeghinejad","year":"2010","journal-title":"Ophthalmic Res"},{"key":"R19-22-20210204","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00347-009-1936-y","article-title":"Antiangiogenic therapy for pterygium recurrence in German.","volume":"106","author":"Leippi","year":"2009","journal-title":"Ophthalmologe"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-201306000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:50:45Z","timestamp":1618278645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201306000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3182772d4e","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}